Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-08-02
2011-08-02
Parkin, Jeffrey S (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C424S196110, C424S208100
Reexamination Certificate
active
07988974
ABSTRACT:
The present invention relates to fusion peptides which exhibit potent anti-retroviral activity. The fusion peptides of the invention comprise a macromolecular carrier group fused to a gp41-derived DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LA1gp41 protein, or fragments, analogs or homologs of DP178. The invention further relates to the uses of such fusion peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4659669 (1987-04-01), Kleid et al.
patent: 4707358 (1987-11-01), Kieff et al.
patent: 4761470 (1988-08-01), Emini et al.
patent: 5057211 (1991-10-01), Baummer
patent: 5075211 (1991-12-01), Cosand et al.
patent: 5116725 (1992-05-01), Vaughan et al.
patent: 5141867 (1992-08-01), Ivanoff et al.
patent: 5156949 (1992-10-01), Luciw et al.
patent: 5444044 (1995-08-01), Jiang et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5840843 (1998-11-01), Jiang et al.
patent: 5853978 (1998-12-01), Berman et al.
patent: 5876969 (1999-03-01), Fleer et al.
patent: 6001977 (1999-12-01), Chang et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6025325 (2000-02-01), Compfield et al.
patent: 6054265 (2000-04-01), Barney et al.
patent: 6248574 (2001-06-01), Shaffermann
patent: 6261564 (2001-07-01), Alizon et al.
patent: 6440656 (2002-08-01), Bolognesi et al.
patent: 6440657 (2002-08-01), Montangnier et al.
patent: 6479055 (2002-11-01), Barney et al.
patent: 6531276 (2003-03-01), Luciw et al.
patent: 6610476 (2003-08-01), Chang et al.
patent: 6858712 (2005-02-01), Chang et al.
patent: 7122190 (2006-10-01), Bolognesi et al.
patent: 7273614 (2007-09-01), Bolognesi et al.
patent: 2007/0037141 (2007-02-01), Bolognesi et al.
patent: 2007/0202123 (2007-08-01), Greenberg et al.
patent: 2007/0202127 (2007-08-01), Bolognesi et al.
patent: 1341476 (2005-03-01), None
patent: 0 284 587 (1988-09-01), None
patent: 0 323 157 (1988-12-01), None
patent: 0 335 134 (1989-10-01), None
patent: 0 362 909 (1990-04-01), None
patent: 0 362 910 (1990-04-01), None
patent: 0 362 927 (1990-04-01), None
patent: 0 565 164 (1993-03-01), None
patent: 0 181 150 (2003-03-01), None
patent: 2677346 (1992-12-01), None
patent: WO 94/28920 (1984-12-01), None
patent: WO 86/01535 (1986-03-01), None
patent: WO 86/02383 (1986-04-01), None
patent: WO 86/04336 (1986-07-01), None
patent: WO 86/06414 (1986-11-01), None
patent: WO 88/05051 (1988-07-01), None
patent: WO 88/05440 (1988-07-01), None
patent: WO 88/08429 (1988-11-01), None
patent: WO 89/02935 (1989-04-01), None
patent: WO 90/07119 (1990-06-01), None
patent: WO 91/09872 (1991-07-01), None
patent: WO 92/00997 (1992-01-01), None
patent: WO 92/22654 (1992-12-01), None
patent: WO 93/14207 (1993-07-01), None
patent: WO 96/40191 (1996-12-01), None
Wild, C. T., et al., 1994, Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection, Proc. Natl. Acad. Sci. USA 91:9770-9774.
U.S. Appl. No. 08/484,223, filed Jun. 7, 1995, Barney et al.
Wild et al., 1992, A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition, Proc. Natl. Acad. Sci USA 89:10537-10541.
Mitsuya et al., 1991, Targeted therapy of human immunodeficiency virus-related disease, FASEB J. 5:2369-2381.
Hammarskjold and Rekosh, 1989, The molecular biology of the human immunodeficiency virus, Biochem. Biophys. Acta 989:269-280.
Guyader et al., 1987, Genome organization and transactivation of the human immunodeficiency virus type 2, Nature 326:662-669.
Clavel et al., 1986, Isolation of a new human retrovirus from West African patients with AIDS, Science 233:343-346.
Maddon et al., 1986, The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain, Cell 47:333-348.
McDougal et al., 1986, Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110k viral protein and the T4 molecule, Science 231:382-385.
Barin et al., 1985, Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients, Science 228:1094-1096.
Dalgleish et al., 1984, The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus, Nature 312:763-767.
Gallo et al., 1984, Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS, Science 224:500-503.
Klatzmann et al., 1984, T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV, Nature 312:767-768.
Teich et al., 1984, Pathogenesis of lentivirus, in “RNA Tumor Viruses” Weiss et al., eds., CSH-Press, pp. 949-956.
Barre-Sinoussi et al., 1983, Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS), Science 220:868-870.
Suzuki et al., 1995, Viral Interleukin 10 (IL-10), the Human Herpes Virus 4 Cellular IL-10 Homologue, Induces Local Anergy to Allogenic and Syngeneic Tumors, J of Experimental Medicine 182:477-486.
Wild et al., 1994, Propensity for a Leucine Zipper-Like Domain of Human Immunodeficiency Virus Type 1 gp41 to Form Oligomers Correlates With a Role in Virus-Induced Fusion Rather Than Assembly of the Glycoprotein Complex, Proc. Natl. Acad. Sci. USA 91:12676-80.
Collins et al., 1984, Nucleotide Sequence of the Gene Encoding the Fusion (F) Glycoprotein of Human Respiratory Syncytial Virus, Proc. Natl. Acad. Sci. USA 81:7683-87.
Smith et al., 1987, Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen, Science 238:1704-1707.
Erickson et al., 1990, Design, Activity, and 2.8 Å Crystal Structure of a C2 Symmetric Inhibitor Complexed to HIV-1 Protease, Science 249:527-533.
Daar et al., 1990, High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates, Proc. Natl. Acad. Sci. USA 87:6574-6579.
Lazinski et al., 1993, Relating Structure to Function in the Hepatitis Delta Virus Antigen, J of Virology 67:2672-80.
Wang et al., 1993, Ion Channel Activity of Influenza A Virus M2 Protein: Characterization of the Amantidine Block, J of Virology 67:5585-94.
Bousse et al., 1994, Regions on the Hemagglutinin-Neuraminidase Proteins of Human Parainfluenza Virus Type-1 and Sendai Virus Important for Membrane Fusion, Virology 204:506-514.
Staden, 1990, Searching for Patterns in Protein and Nucleic Acid Sequences, Meth. Enzymol. 183:193-211.
Staden, 1994, Using Patterns to Analyze Protein Sequences, Chapter 13 in: Methods in Molecular Biology, vol. 25, Griffin et al., eds., Humana Press, Inc., Totowa, NJ, p. 141-154.
Staden, 1994, Searching for Motifs in Protein Sequences, Chapter 12 in: Methods in Molecular Biology, vol. 25, Griffin et al., eds., Humana Press, Inc., Totowa, NJ, p. 131-139.
Bousse et al. 1995, A single amino acid changes enhances the fusion promotion activity of human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein. Virology. 209(2):654-7.
Geysen et al. 1988, Cognitive features of continuous antigenic determinants. J. Molec. Recog. 1:33-41.
Wildner et al. 1997 Database screening for molecular mimicry. Immunol Today 18(5):252.
Roudier J. 1997, Response to Wildner et al. and Burns et al. Immunol Today 18(5): 252.
Hall CB. 1994, Prospects for a respiratory syncytial virus vaccine. Science. 2;265(5177):1393-4. Review.
Toms GL. 1995, Respiratory syncytial virus—how soon will we have a vaccine? Arch Dis Child. 72(1):1-3.
Benet et al. 1990, Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination, inThe Pharmacological Basis of Therapeutics, Goodman et al., eds., Pergammon Press, New York, pp. 3-32.
Flexner C. and Hendrix, C., 1997, Pharmacology of anti-retroviral agents. InAIDs: Biology, Diagnosis, Treatment and Prevention. 4thEdition, DeVita et al. Eds., Lippincott-Raven Publishers, pp. 479-493.
Yarchoan et al. 1992, Correlations between the in vitro and in vivo activity of anti-HI
Chen Chin-Ho
Greenberg Michael L.
Matthews Thomas James
Duke University
Jones Day
Parkin Jeffrey S
LandOfFree
Antifusogenic proteins comprising human immunodeficiency... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antifusogenic proteins comprising human immunodeficiency..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antifusogenic proteins comprising human immunodeficiency... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2787254